Early ART and testing HIV negative with rapid HIV tests

On-demand dosing for PrEP is highly effective in French expanded access programme

New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex

New guides to PrEP

STOPAIDS reviews DFID’s work on HIV and AIDS

US HIV pain management guidelines (IDSA)

Generic PrEP in France and Scotland challenges access across the UK

PrEP use in adolescent gay and bisexual men: US study shows need for easier access and easier PrEP

UK PrEP guidelines: online for comment

The evidence for Undetectable = Untransmittable (U=U): why negligible risk is zero risk

July/August 2017: Volume 18 Number 7/8

HIV Pipeline Report (2017)

Fit for Purpose: HIV treatment optimisation for adults and children (2017)

i-Base 2017 appeal: we need your help….

9th IAS Conference on HIV Science (IAS 2017)

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population

Swaziland nearly halves HIV incidence in five years

Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U

HIV remission news from IAS 2017

Publications launched at IAS 2017

9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris

Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy

First dolutegravir-based FDC gets FDA tentative approval

FDA grant priority review for ibalizumab

Controversial PrEP study from NHS England due to start in September

UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’

July/August 2017: Volume 18 Number 7/8

FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US

Future meetings 2017/2018

Featured Introduction to HIV pipeline 2017

HIV pipeline 2017: full version

HIV pipeline 2017: summary version

HIV pipeline 2017: Update from IAS Paris

HIV pipeline 2017 PDFs

Fit for purpose (July 2017)

Antiretroviral treatment optimisation for adults and children

HIV pipeline 2017: summary version

The paediatric pipeline 2017

Fit for purpose 2017 PDF

May/June 2017: Volume 18 Number 5/6

ART in pictures: HIV treatment explained (June 2017)

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago

Dolutegravir pharmacokinetics in pregnancy

High rates of of undocumented efavirenz-related side effects in Uganda

11th INTEREST Workshop, 16-19 May 2017, Lilongwe, Malawi

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Impressive HIV pipeline at CROI 2017

Paediatric HIV: CROI 2017

WHO adds dolutegravir and PrEP to updated Essential Medicine List

Dolutegravir/rilpivirine submitted to EMA and FDA as oral two-drug maintenance combination

Bictegravir/FTC/TAF: new once-daily integrase-based FDC submitted to US FDA

Post navigation